A Randomized Dose-ranging Controlled Trial of DU-176b Versus Warfarin Potassium in Patients With Non-valvular Atrial Fibrillation

Trial Profile

A Randomized Dose-ranging Controlled Trial of DU-176b Versus Warfarin Potassium in Patients With Non-valvular Atrial Fibrillation

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Mar 2015

At a glance

  • Drugs Edoxaban (Primary) ; Warfarin
  • Indications Atrial fibrillation; Cerebral infarction; Embolism; Intracranial haemorrhages; Stroke; Thromboembolism; Thrombosis
  • Focus Adverse reactions
  • Sponsors Daiichi Sankyo Company
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 15 Jul 2009 Results were presented at the 22nd Congress of the International Society on Thrombosis and Haemostasis.
    • 31 Jan 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top